Gilead-backed Kite to acquire Interius BioTherapeutics for $350m.

Gilead-backed Kite, a biopharmaceutical company, agreed to acquire Interius BioTherapeutics, a clinical stage biotechnology company, for $350m. “In vivo therapy is a promising frontier with the potential to transform how we approach treating patients, shifting to more accessible and scalable solutions. By combining Interius’s teams and their novel platform with Kite’s deep expertise and footprint in cell therapy research, development and manufacturing, we aim to advance best-in-class in vivo therapies to bring them to patients more efficiently,” Cindy Perettie, Kite Executive Vice President.